Days after reports of Novavax Inc.’s experimental Covid-19 vaccine candidate producing antibodies in healthy patients in a clinical study, the company announced a license agreement with Serum Institute of India Private Limited (SIPL) to develop up to 1 billion doses of the preventative drug in India and other countries.
Novartis’ Sandoz division will not profit from 15 generic drugs the company is making available to developing countries to treat symptoms of Covid-19 for the pandemic’s duration, the Swiss drugmaker said.
AstraZeneca announced plans to manufacture 2 billion doses of the University of Oxford’s COVID-19 vaccine, AZD122.
The U.S. spends about twice what other high-income nations do on health care but has the lowest life expectancy and the highest infant mortality rates, a new study suggests.
GlaxoSmithKline is to adopt a graduated approach to patenting its medicines, depending on the wealth of different countries, in order to make drugs more affordable in the developing world. Britain’s biggest drugmaker said on Thursday it would not file patents in low-income states, leaving the way clear for generic companies to make cheap copies […]